InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

OKYO Pharma Ltd

OKYO Clue Score22
United Kingdom CIK 0001849296
$1.42 +2.16% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.42 −29.70% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 17 May 2022. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Net income
Fiscal year 2020Net income−1.5Fiscal year 2021Net income−3.4EPS, diluted−0.32Fiscal year 2022Net income−5.4EPS, diluted−0.36Fiscal year 2023Net income−13.3EPS, diluted−0.61Fiscal year 2024Net income−16.8EPS, diluted−0.57Fiscal year 2025Net income−4.7EPS, diluted−0.20
FY2020FY2021FY2022FY2023FY2024FY2025
Net income −1.5 −3.4 −5.4 −13.3 −16.8 −4.7
Growth
EPS, diluted n/a −0.32 −0.36 −0.61 −0.57 −0.20
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−1.2Fiscal year 2021Operating cash flow−1.6Capital expenditure−0.0Free cash flow−1.6Fiscal year 2022Operating cash flow−5.5Capital expenditure−0.0Free cash flow−5.5Fiscal year 2023Operating cash flow−7.7Capital expenditure−0.0Free cash flow−7.7Fiscal year 2024Operating cash flow−9.5Fiscal year 2025Operating cash flow−1.8Capital expenditure−0.0Free cash flow−1.8
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −1.2 −1.6 −5.5 −7.7 −9.5 −1.8
Capital expenditure n/a −0.0 −0.0 −0.0 n/a −0.0
Free cash flow n/a −1.6 −5.5 −7.7 n/a −1.8
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash0.2Shareholders’ equity−0.1Fiscal year 2021Cash6.9Shareholders’ equity5.3Fiscal year 2022Cash2.7Shareholders’ equity2.9Fiscal year 2023Cash4.0Shareholders’ equity−2.1Fiscal year 2024Cash0.8Shareholders’ equity−5.9Fiscal year 2025Cash1.6Shareholders’ equity−5.5
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 0.2 6.9 2.7 4.0 0.8 1.6
Shareholders’ equity −0.1 5.3 2.9 −2.1 −5.9 −5.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending March, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Mar 2020 FY2021 31 Mar 2021 FY2022 31 Mar 2022 FY2023 31 Mar 2023 FY2024 31 Mar 2024 FY2025 31 Mar 2025
Revenue and profit
0.5 0.3 1.6 6.3 8.2 2.3
−1.6 −3.4 −6.2 −13.3 −16.8 −8.0
0.1 0.0 0.8 0.0 −0.0 3.3
−1.5 −3.4 −5.4 −13.3 −16.8 −4.7
Growth
Per share
n/a −0.32 −0.36 −0.61 −0.57 −0.20
n/a −0.32 −0.36 −0.61 −0.57 −0.20
Growth
595.5 672.8 979.2 n/a n/a n/a

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 6 of 6 years on file.